• Launch of Zioprol, a bioequivalent Bisoprolol generic, for the treatment of patients with hypertension, heart failure and angina.
• Launch of Algomiel (Carbinoxamine Maleate, Dextronmethorphan Hydrobrimide, Sodium Citrate in a soothing of honey base) an anti-cough syrup indicated for the treatment of bronchitis and broncho-pneumonia, whooping cough and chronic cough.
• Launch of Triltec (Ramipril) in Kuwait; It is indicated for the management of hypertension and the reduction of risks of MI, stroke and death in high risk patients.
• Launch of Contrave in KSA, a unique anti-obesity medication works on both hunger and craving.
• Launch of Tergynan in Lebanon, an anti-fungal medication.

• Launch of Blovek in Lebanon, a bioequivalent Nebivolol generic for the treatment of hypertension and heart failure.
• Launch of Diaflozin in Lebanon, the 1st and only bioequivalent Dapagliflozin generic for the treatment of diabetic and non-diabetic HF/CKD patients.
• Launch of Exentazil in Lebanon, the breakthrough once daily XR Memantine and Donepezil  combination that works on two pathways in the brain to treat patients suffering from moderate to severe Alzheimer's disease.
• Launch of Flobiox in Lebanon, a unique bioequivalent Levofloxacin having a flexibility of dosing and a wide antimicrobial spectrum.
• Launch of Vludin/ Vludin met in Lebanon, the first and only bioequivalent Vildaglitin generic for the treatment of diabetic and early diabetic patients.
• Launch of Zitera in Lebanon, a levetiracetam broad-spectrum anti-epileptical used in the treatment of seizures in Epilepsy for adults and pediatric patients.
• Launch of Contrave in Oman, a unique anti-obesity medication that works on both hunger and craving.

• Launch of Avixan in Lebanon, the first and only bioequivalent Apixaban generic for the prevention and treatment of patients with DVT, PE and Afib.
• Launch of Klotego  in Lebanon, the first and only bioequivalent Ticagrelor generic for ACS management.
• Launch of Ribavan in Lebanon, the bioequivalent Rivaroxaban for the prevention and treatment of patients with DVT, PE and Afib and patients with CAD at risk of atherothrombotic events.
• Launch of Alvigo in Lebanon, a bioequivalent Betahistine Dihydrochloride generic that alleviates symptoms of Meniere's disease.

• Launch of Nozentrix in Lebanon, a bioequivalent Ondansetron for the prevention of nausea and vomiting in patients undergoing chemotherapy, radiotherapy and surgery.

• Launch of 123 complete in Lebanon, a combination of (Paracetamol, Dextromethorphan, Phenylephrine Hydrochloride and Carbinoxamine) that provides patients with 24H complete relief of cold, cough & flu.

• Launch of Adenuric (febuxostat) in Bahrain, a breakthrough in the management of gout.
• ​Launch of Smectalia (diosmectite) strawberry flavor in Lebanon. Smectalia is the first line treatment of acute and chronic diarrhea for children and adults.

Launch of Zorvolex (diclofenac) in UAE, the first and only FDA-approved low dose nonsteroidal anti-inflammatory drug developed using proprietary SoluMatrix Fine Particle Technology™.

• Launch of Adenuric (febuxostat) in Kingdom of Saudi Arabia, a breakthrough in the management of gout.
• Groundbreaking Ceremony of New Manufacturing plant in Lebanon.

• Launch of Zorvolex (diclofenac) the first and only FDA-approved low dose nonsteroidal anti-inflammatory drug developed using proprietary SoluMatrix Fine Particle Technology™.
• Launch of Livazo (pitavastatin) in Kingdom of Saudi Arabia, a novel efficacious and differentiated statin.
• Launch of Adenuric (febuxostat) in Kuwait, Jordan and United Arab Emirates, a breakthrough in the management of gout.
• Launch of Silosin (silodosin) in Qatar indicated for benign prostatic hyperplasia.

• Launch of Livazo (pitavastatin) in Kuwait and United Arab Emirates, a novel efficacious and differentiated statin.

• Launch of Livazo (pitavastatin) in Jordan under-license from Kowa, a novel efficacious and differentiated statin.
• Algorithm acquired from Ipsen the secondary packaging and marketing authorization for Smecta / Smectalia (diosmectite). Smectalia is the first line treatment of acute and chronic diarrhea for children and adults.

• Launch of Adenuric (febuxostat) in Lebanon under-license from Teijin. Adenuric is a breakthrough in the management of gout.

• Launch of Livazo (pitavastatin) under-license from Kowa in Lebanon, a novel efficacious and differentiated statin

• Launch of Silosin (silodosin, under license from Recordati & Kissei) indicated for benign prostatic hyperplasia. The launch in Lebanon was the 3rd one worldwide after the launches in Japan and United States of America.
• Launch of Zanipress, the only antihypertensive with a fixed combination of a Dihydropiridine Calcium Antagonist (lercanidipine) and an ACE Inhibitor (enalapril), also under license form Recordati

• Regional agreement with Ipsen to promote its portfolio 

• Partnership with Iroko Cardio LLC on Aggrastat (tirofiban). Marketing in the Middle East granted to Algorithm.
• Expansion of the partnership with Lilly to include promotion of products in the Gulf: Glustin, Prozac and Evista

• Partnership with Eli Lilly focusing on the Lebanese market

• Launch of Lercadip (lercanidipine); the first 3rd generation lipophilic Calcium Antagonist Dihydropiridine indicated for Hypertension.
• Launch of the first one shot gynecological antifungal treatment, Lomexin (fenticonazole).
• Launch of Urispas (flavoxate) creating the untapped market of urge incontinence
• Launch of the first generic: Captace (captopril) enhancing the presence of Algorithm in the cardiovascular field

• Partnership with Recordati to manufacture and promote its products in the Middle East, namely Lercadip, Lomexin and Urispas

• Ownership transferred to a group of Lebanese nationals, shareholders of Drogureie de L'Union - distributors of MSD in Lebanon. The company name was changed to ALGORITHM SAL. All manufactured products were still under license from MSD

• Plant established in Lebanon as "CHARLES. E. FROSST & CO. (M.E.) S.A.L". It was initially built in 1961 and later expanded in 1974. It has operated as a subsidiary of MERCK & CO. INC. (MSD) until December 1989.